Focal laser ablation for prostate cancer followed by radical prostatectomy: validation of focal therapy and imaging accuracy

Uri Lindner; Nathan Lawrentschuk; Robert A Weersink; Sean R H Davidson; Orit Raz; Eugen Hlasny; Deanna L Langer; Mark R Gertner; Theodorus Van der Kwast; Masoom A Haider; John Trachtenberg

doi:10.1016/j.eururo.2010.03.008

Focal laser ablation for prostate cancer followed by radical prostatectomy: validation of focal therapy and imaging accuracy

Eur Urol. 2010 Jun;57(6):1111-4. doi: 10.1016/j.eururo.2010.03.008. Epub 2010 Mar 12.

Authors

Uri Lindner¹, Nathan Lawrentschuk, Robert A Weersink, Sean R H Davidson, Orit Raz, Eugen Hlasny, Deanna L Langer, Mark R Gertner, Theodorus Van der Kwast, Masoom A Haider, John Trachtenberg

Affiliation

¹ Surgical Oncology, Urology Division, University Health Network, University of Toronto, Toronto, Canada. lindneruri@gmail.com

PMID: 20346578
DOI: 10.1016/j.eururo.2010.03.008

Abstract

An increased incidence of low-risk prostate cancer (PCa) has led investigators to develop focal therapy as a management option for PCa. We evaluated the effects of focal laser ablation (FLA) on PCa tissue and the accuracy of magnetic resonance imaging (MRI) in determining ablated lesion volume by comparing the whole-mount histology and MRI in four patients that underwent FLA followed by radical prostatectomy. Ablated areas were characterized by homogeneous coagulation necrosis. The MRI-calculated ablated volume correlated well with histopathology. We found that FLA creates confluent ablation with no evidence of viable cells in treated regions. Postablation MRI is able to determine the ablation accurately.

Trial registration: ClinicalTrials.gov NCT00805883.

Publication types

Case Reports
Validation Study

MeSH terms

Aged
Humans
Laser Therapy / methods*
Magnetic Resonance Imaging / methods*
Male
Middle Aged
Prostatectomy
Prostatic Neoplasms / pathology*
Prostatic Neoplasms / surgery*

Associated data

ClinicalTrials.gov/NCT00805883